Reading SANA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SANA free→Reading SANA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SANA free→QuarterlyIQ Insights · SANA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 11, 2026, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or othe…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. In order to achieve a more equal balance of director membership among the three classes of the Board of Directors (“Board”) of Sana Biotechnology, Inc. (the “Company”) in accordance with the Company’s Amended and Restated Certificate of Incorporation (“Certificate of Incorporation”), the Board determined that one of its Class I directors (with a te…
Other Events. On April 10, 2026 (the “Effective Date”), Sana Biotechnology, Inc. (the “Company”) entered into a stock purchase agreement (the “Stock Purchase Agreement”) with Mayo Clinic, pursuant to which the Company agreed to sell to Mayo Clinic, and Mayo Clinic agreed to purchase from the Company, (i) 7,507,507 shares (the “Initial Shares”) of the Company’s common stock, $0.0001 par value per share (“Common Stock”), at a price of $3.33 per share (the “Per Share Purchase Price”), for gross…
Other Events. On March 3, 2026, the Company entered into an amended and restated sales agreement (the “Sales Agreement”) with TD Securities (USA) LLC (“TD Cowen”) to sell shares of the Company’s common stock, $0.0001 par value per share (“Common Stock”), from time to time, through an “at the market offering” program under which TD Cowen will act as sales agent. The Sales Agreement amends and restates the prior sales agreement, dated May 8, 2025, between the Company and TD Cowen (the “Prior Sa…
Results of Operations and Financial Condition. On March 3, 2026, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange A…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Executive Vice President, Chief Financial Officer, and Treasurer, and Transition of Principal Financial Officer On February 17, 2026, Sana Biotechnology, Inc. (the “Company”) announced that Brian Piper, M.B.A., joined the Company as Executive Vice President, Chief Financial Officer on February 17, 2026 (the “Commencement Date”), and…
Results of Operations and Financial Condition. On November 6, 2025, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),…
of this Current Report, the Company has entered into an offer letter with Aaron M. Grossman pursuant to which Mr. Grossman is expected to commence employment, effective as of October 20, 2025, as the Company’s Executive Vice President, Chief Legal Officer. Cautionary Note Regarding Forward-Looking Statements This Current Report contains forward-looking statements regarding Mr. Cassidy’s retirement and the commencement of Mr. Grossman's employment as his successor. These forward-looking statem…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 28, 2025, Mary Agnes Wilderotter notified Sana Biotechnology, Inc. (“Sana”) of her decision to resign from the Board of Directors (“Board”) of Sana Biotechnology, Inc. (“Sana”), including from her positions as Chairperson of the Nominating and Corporate Governance Committee of the Board and a member of the Audit Committee of the Board, ef…
Results of Operations and Financial Condition. On August 11, 2025, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or ot…
Entry into a Material Definitive Agreement. On August 6, 2025, Sana Biotechnology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, and BofA Securities, Inc., as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering (the “Offering”) of 20,895,522 shares of the Company’s common st…
Results of Operations and Financial Condition. The information set forth in
Other Events. On May 8, 2025, the Company entered into a sales agreement (“Sales Agreement”) with TD Securities (USA) LLC (“TD Cowen”) to sell shares of the Company’s common stock, $0.0001 par value per share (“Common Stock”), having an aggregate offering price of up to $119.0 million, from time to time, through an “at the market offering” program under which TD Cowen will act as sales agent. Immediately prior to entering into the Sales Agreement, the Company terminated its sales agreement, d…
Results of Operations and Financial Condition. On May 8, 2025, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or other…
Results of Operations and Financial Condition. On March 17, 2025, Sana Biotechnology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.